Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Int Immunopharmacol. 2020 Jul;84:106535. doi: 10.1016/j.intimp.2020.106535. Epub 2020 Apr 29.
During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer stem cells (BCSCs) are the main player in the aggressiveness of different tumors and also, these cells are the main challenge in cancer treatment. Moreover, the major obstacle to achieve an effective treatment is resistance to therapies. There are various types of treatment for breast cancer (BC) patients. Therefore, in this review, we present the current treatments, novel approaches such as antibody-drug conjugation systems (ADCs), nanoparticles (albumin-, metal-, lipid-, polymer-, micelle-based nanoparticles), and BCSCs-based therapies. Furthermore, prognostic and predictive biomarkers will be discussed also biomarkers that have been applied by some tests such as Oncotype DX, Mamm αPrint, and uPA/PAI-1 are regarded as suitable prognostic and predictive factors in breast cancer.
在过去的几年中,各种疗法在乳腺癌时代出现。乳腺癌是一种涉及遗传和环境因素的异质性疾病。乳腺癌干细胞(BCSCs)是不同肿瘤侵袭性的主要参与者,也是癌症治疗的主要挑战。此外,实现有效治疗的主要障碍是对治疗的耐药性。乳腺癌(BC)患者有多种治疗方法。因此,在这篇综述中,我们介绍了目前的治疗方法,以及一些新的方法,如抗体药物偶联系统(ADCs)、纳米颗粒(基于白蛋白、金属、脂质、聚合物、胶束的纳米颗粒)和基于 BCSC 的治疗方法。此外,还讨论了预后和预测生物标志物,以及一些测试中应用的生物标志物,如 Oncotype DX、Mamm αPrint 和 uPA/PAI-1,被认为是乳腺癌的合适预后和预测因素。
Int Immunopharmacol. 2020-7
Semin Cancer Biol. 2017-9-4
Curr Stem Cell Res Ther. 2019
Breast Cancer Res. 2014-8-22
Biomed Pharmacother. 2018-6-23
Pharmacogenomics. 2015
Breast Cancer Res. 2015-1-27
Naunyn Schmiedebergs Arch Pharmacol. 2025-9-5
Ann Med Surg (Lond). 2025-6-16
Front Oncol. 2025-7-30